IQVIA Regulatory Intelligence offers expanded country coverage in the Software as Medical Device cross-country table, enabling you to easily access essential information for launching and maintaining a SaMD product in 10 key markets. Contact us to streamline your regulatory journey. https://bit.ly/45ZD8Y8 #RegulatoryIntelligence
IQVIA Global Market Insights
Pharmaceutical Manufacturing
Durham, North Carolina 19,356 followers
About us
Through our Gold Standard data and analytics, Global Market Insights supports pharmaceutical and life sciences organizations in measuring, managing and segmenting markets, finding and sizing opportunities and maximizing the return on investment across the pharmaceutical drug lifecycle worldwide.
- Website
-
https://www.iqvia.com
External link for IQVIA Global Market Insights
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Durham, North Carolina
Updates
-
Are hematology drugs reaching patients across Europe? IQVIA Institute aims to answer this question in our latest report, Hematologic Cancer Opportunities for Patient Equality (HOPE). This chart assesses the volume use of novel hematological cancer medicines, by applying the WHO Defined Daily Dose (WHO-DDD) metric IQVIA audited medicine volumes in this chart. 🩸 There may be differences in the medicines evaluated. This highlights the variability in country-level prioritization of certain types of novel medicines for a variety of cancers. 🩸 The UK and France had utilization levels nearly 50% higher than the European average. Australia, Canada, and Italy also had DDD per capita in 2023 above the European average. 🩸 Central and Eastern European countries tend to have lower utilization of these medicines though all have similar DDD per capita in 2023. These countries range from 37% to 44% below the European average. 🩸 Typically, wealthier countries have higher utilization of essential innovative medicines as these countries tend to have more economic resources to devote to healthcare. Download Hematologic Cancer Opportunities for Patient Equality (HOPE) to learn more about the availability of hematology cancer treatments for patients across countries: https://bit.ly/4cSBKIY. #IQVIAMIDAS #Oncology #PharmaSpending.
-
-
There has been a consistent rise in innovative branded product launches in China in recent years, whereas launches have decreased in other countries such as the UK and Japan. Discover the factors driving this growth in our latest article. https://bit.ly/3XZk5eq #ForecastLink #ChinaMarket #NonBiologics #ChinaPharma
-
Are you leveraging the power of personalization in #HCPengagement? Today's #HCPengagement requires a customer-centric approach that prioritizes the balance between personal and non-personal channels, as well as the advantages of outsourcing in #LifeSciences. Delve into our latest white paper to discover essential strategies for cultivating robust relationships with #HCPs and learn how the integration of #data and #technology can foster a genuinely personalized #CustomerExperience. ➡️ https://bit.ly/3XTSfAc #ChannelDynamics
-
-
Pinpoint trial locations and tailor your decision-making to specific regions and markets. Trial Link's detailed geographical insights open a new dimension in strategic planning and execution. Request a demo today https://bit.ly/3zADwAg #IQVIATrialLink #ClinicalTrialsAnalysis #AnalyticsLinkEcosystem
-
Launch excellence has become a rare achievement. Hear from our expert Kirstie Scott, Senior Consultant, EMEA Thought Leadership team, and don’t miss the resources we created for you to develop a successful #launch strategy. https://bit.ly/3Lx27c1 #LaunchExcellence
-
According to the Global Trends in R&D 2024 report, next-generation biotherapeutics now make up 25% of the hematological-oncology pipeline. Download the latest: https://bit.ly/3xxrd7e. #RandD #PipelineLink #ArkPatentIntelligence #PharmaDeals
-
-
Join this on demand webinar to enhance your understanding of advancing omnichannel capabilities to drive to long-term success of your HCP engagement and deliver a trusted HCP customer experience. https://bit.ly/4ctSYNc #ChannelDynamics #Omnichannel #HCPEngagement #CustomerEngagement
-
-
Exploring the primary endpoints for upcoming drugs is crucial to understand the future competitive market. Find out how Trial Link can help you fine tune your market positioning adding clinical trials to your market analysis. #MarketAccess #IQVIATrialLink #ClinicalTrials #AnalyticsLinkEcosystem https://bit.ly/3zu79mH
-
-
Big pharma companies are back at the dealmaking table! Q1 2024 marked the resurgence of big pharma companies in M&A, with 15% of transactions involving a top-ranked pharma company. Dive into the implications of big pharma’s returning to dealmaking. https://bit.ly/3xEOiEV #PharmaDeals #Dealmaking #MandA
-